A new generation of medicines

WE ARE DEDICATED TO DEVELOPING NOVEL MEDICINES TO TRANSFORM THE LIVES OF PATIENTS WITH HORMONE RECEPTOR POSITIVE CANCERS 

 
 
Home Banner.jpg
 
Biomarkers Icon

Focus On HR+ Cancers

Hormone receptor positive (HR+) cancers, including, prostate, breast, and ovarian result in >100,000 deaths per year in the United States. Decades old antihormonals and chemotherapies are still the most used therapies to treat these cancers. 

Therapeutic Focus Icon

Apristor® For PR+ Breast Cancer

Our most advanced clinical-stage program, Apristor, is being investigated in breast and ovarian cancers. Because Apristor is the first pure progesterone receptor (PR) antagonist, the drug has the potential to improve overall survival by providing more complete hormonal blockade than dual PR agonist/antagonists.

latest news
Social media